Verano Holdings' $195M Bet: How Cannabis MSOs Are Refinancing to Survive
Advertisement
On March 11, 2026, Chicago-based cannabis multistate operator Verano Holdings quietly closed one of the largest lending deals in cannabis history: a $195 million senior secured term loan designed to retire old debt and position the company for what it calls "a busy 2026." The deal, backed by Needham Bank and Chicago Atlantic Financial Services at a 9.5% annual interest rate, tells a bigger story about the financial pressure facing America's largest cannabis companies — and the creative survival strategies they are deploying to stay alive.
Table of Contents
- The Debt Wall
- Why 9.5% Is Actually a Good Deal
- The Broader MSO Debt Crisis
- Refinancing vs. Restructuring
- What Rescheduling Could Change
- The CLIMB Act Factor
- What This Means for Consumers
- What Comes Next — and When
The Debt Wall
Verano's refinancing was not optional. The company had $350 million in debt coming due in 2026, part of a broader $400 million debt load accumulated during the industry's frenzied expansion years. When cannabis companies were racing to acquire licenses, build cultivation facilities, and open dispensaries across multiple states between 2019 and 2022, they financed that growth with high-interest private debt — often the only financing available to businesses locked out of traditional banking.
Now those loans are maturing, and the bill is coming due across the entire sector. According to MJBizDaily, billions of dollars in cannabis industry debt will mature in 2026, creating what analysts have described as a "debt avalanche" that threatens to push overleveraged operators into bankruptcy or forced asset sales.
Verano's $195 million term loan, combined with drawing the remaining $50 million from its existing $100 million revolving credit facility, allows the company to "pay off and terminate" the debt it took out in 2022. Monthly payments of $875,000 begin in April, with the loan maturing in 2029.
Why 9.5% Is Actually a Good Deal
In any other industry, borrowing at 9.5% annual interest would raise eyebrows. In cannabis, it is considered favorable. The federal prohibition that prevents cannabis companies from accessing traditional bank lending means operators routinely pay 12% to 20% or higher on private debt.
Some emergency bridge loans in the cannabis space have carried interest rates approaching 25%.
Verano's ability to secure 9.5% reflects several factors: its scale (operations in 13 states), its revenue trajectory (projected positive cash flow in 2026), and the growing confidence of niche lenders who have developed expertise in cannabis compliance. Needham Bank, a Massachusetts institution, has emerged as one of the most active cannabis lenders in the country, willing to underwrite deals that major national banks still refuse to touch.
Chicago Atlantic Financial Services, the other participant in the deal, has built its entire business model around lending to cannabis operators. The firm manages over $1 billion in cannabis-related assets and has positioned itself to profit from the industry's inability to access mainstream capital markets.
The Broader MSO Debt Crisis
Verano is far from alone in facing a 2026 debt reckoning. Across the multistate operator landscape, companies that expanded aggressively during the 2020-2022 cannabis boom are now confronting the financial consequences of that growth.
The math is punishing. Cannabis MSOs took on massive debt to acquire state licenses that cost millions of dollars each, build out cultivation and manufacturing facilities, and open retail locations. They did this while paying effective federal tax rates of 70% or higher under Section 280E [Quick Definition: IRS code barring cannabis businesses from deducting normal expenses like rent and payroll], which prevents cannabis businesses from deducting most normal operating expenses.
Revenue growth in many markets has stalled or declined as oversupply pushed wholesale prices down by 40% to 60% from their peaks.
The result is an industry where many of the largest operators have negative book value, meaning their liabilities exceed their assets. Ascend Wellness reported a higher operating loss in its most recent quarter. PharmaCann announced in March 2026 that it would shut down its Denver cultivation facility and eliminate 132 jobs, citing the financial squeeze in Colorado's oversaturated market.
Refinancing vs. Restructuring
The critical distinction in 2026 is between operators who can refinance their debt — extending maturities and potentially lowering interest rates — and those who cannot. Companies with strong revenue, positive cash flow trajectories, and valuable license portfolios can attract lenders willing to roll over debt on manageable terms. Verano falls into this category.
Operators without those attributes face far grimmer prospects. For companies that cannot refinance, the options narrow to asset sales (often at distressed prices), mergers with better-capitalized competitors, or outright bankruptcy. The cannabis industry has already seen a wave of consolidation driven by financial distress, and 2026 is accelerating that trend.
The recent acquisition of a prominent Colorado cannabis retail chain is just one example of the national industry entering what observers call a new phase of consolidation — one driven not by strategic growth but by financial necessity.
What Rescheduling Could Change
The looming possibility of marijuana rescheduling from Schedule I to Schedule III [Quick Definition: A mid-level federal drug classification including ketamine and testosterone] has added a wildcard to every financial calculation in the cannabis industry. If rescheduling occurs, the elimination of Section 280E would dramatically improve cash flows for every licensed operator, potentially turning unprofitable companies into viable businesses overnight.
Prediction market data from Polymarket suggests roughly even odds of rescheduling by year-end 2026, with 30.5% probability by June 30. This uncertainty creates a complex dynamic for both lenders and borrowers. Operators are trying to survive long enough to benefit from rescheduling, while lenders are pricing their loans based on the possibility that the regulatory landscape could shift dramatically within the loan term.
Verano's 2029 maturity date on its new loan is strategically significant — it provides a three-year runway that encompasses the most likely timeline for rescheduling to be finalized and implemented. If 280E relief materializes, the company's financial picture improves substantially, making the 9.5% interest rate look increasingly attractive in hindsight.
The CLIMB Act Factor
Adding another dimension to the financial outlook, Representatives Guy Reschenthaler and Troy Carter filed the bipartisan CLIMB Act in March 2026, which would allow state-legal cannabis companies to list on major stock exchanges like the NYSE and Nasdaq. Currently, most publicly traded cannabis companies are confined to the Canadian Securities Exchange or over-the-counter markets in the United States, limiting their access to institutional investors and public capital.
If the CLIMB Act passes, cannabis MSOs could potentially raise equity capital through traditional public offerings — a financing channel that has been essentially closed to them. This would reduce the industry's dependence on high-interest private debt and could accelerate the financial stabilization that companies like Verano are pursuing through refinancing.
What This Means for Consumers
The cannabis industry's financial struggles may seem like a Wall Street concern, but they have direct consequences for consumers. Companies under financial pressure cut costs, which can mean reduced product quality, fewer new product launches, store closures, and layoffs that hollow out the customer experience.
Price wars driven by oversupply and financial desperation have already pushed cannabis prices to historic lows in many markets. While cheap weed sounds appealing, the race to the bottom undermines the economics needed to sustain quality cultivation, rigorous testing, and the kind of customer service that builds a legitimate retail industry.
The consolidation wave also reduces consumer choice. As struggling operators sell their licenses to larger companies, the diversity of brands and products on dispensary shelves may narrow. The craft cannabis [Quick Definition: Small-batch, artisanal cannabis grown with emphasis on quality over volume] movement, which has been gaining momentum in states like Minnesota and Oregon, faces particular vulnerability as small operators lack the financial reserves to weather industry turbulence.
What Comes Next — and When
Verano's $195 million refinancing is a survival move, but it is also a statement of confidence — a bet that the cannabis industry's financial environment will improve enough within three years to justify the investment. Whether that bet pays off depends on variables largely outside the company's control: the timing of rescheduling, the trajectory of state-level legalization, and whether Congress can muster the political will to pass banking reform.
For the broader cannabis industry, 2026 is shaping up as a year of financial reckoning. The companies that emerge on the other side will be leaner, more disciplined, and better positioned for the regulated market that is slowly taking shape. The ones that do not will become cautionary tales about the cost of building an industry while fighting federal prohibition.
Pull-Quote Suggestions:
"The company had $350 million in debt coming due in 2026, part of a broader $400 million debt load accumulated during the industry's frenzied expansion years."
"Verano's $195 million term loan, combined with drawing the remaining $50 million from its existing $100 million revolving credit facility, allows the company to "pay off and terminate" the debt it took out in 2022."
"The firm manages over $1 billion in cannabis-related assets and has positioned itself to profit from the industry's inability to access mainstream capital markets."
Why It Matters: Verano Holdings secured a $195 million loan to refinance old debt. Here's what the deal reveals about the cannabis industry's financial reckoning in 2026.